Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Subscribe To Our Newsletter & Stay Updated
